Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | EED | O75530 | 1/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.40 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.40 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474228 | 0.88 | CYP2D6 (0.37) | HTR2A | |
| SCHEMBL100685 | 0.79 | ALDH1A1 (0.53) | EPHX2GPR119ALDH1A1EEDRBBP4 | |
| SCHEMBL100670 | 0.78 | YAP1 (0.51) | GPR119MEN1KMT2AALDH1A1 | |
| SCHEMBL3911173 | 0.72 | LIPE (0.48) | EPHX2GPR119ALDH1A1STS | |
| SCHEMBL20231480 | 0.72 | GPR119 (0.54) | GPR119ALDH1A1 | |
| SCHEMBL3904222 | 0.70 | PDE4D (0.50) | GPR119ALDH1A1STS | |
| SCHEMBL3165742 | 0.70 | PDE4B (0.49) | GPR119ALDH1A1EEDRBBP4SUZ12 | |
| SCHEMBL99961 | 0.69 | YAP1 (0.49) | GPR119MEN1KMT2A | |
| SCHEMBL3904350 | 0.69 | PDE4B (0.48) | GPR119ALDH1A1STS | |
| SCHEMBL22284364 | 0.68 | GPR119 (0.45) | EPHX2GPR119ALDH1A1EEDRBBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205593-B1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2016-01-13 | — | — | EP | disclosed |
| EP-2416777-B1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI SA (FR) | 2014-11-12 | — | — | EP | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8846654-B2 | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748441-B2 | Therapeutic uses of quinazolinedione derivatives | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2411009-B1 | Therapeutic uses of quinazolinedione derivatives | SANOFI SA (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | disclosed |
| US-8242126-B2 | Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2012-08-14 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298298-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | PPARD, DPP4, NDUFB7 | EPHX2 2174/4885GPR119 66/4885MEN1 4072/4885 |
| US-20120184522-A1 | THERAPEUTIC APPLICATIONS IN THE CARDIOVASCULAR FIELD OF QUINAZOLINEDIONE DERIVATIVES | FABP3, SLC5A1, SLC5A2 | EPHX2 2179/4885GPR119 574/4885MEN1 3005/4885 |
| US-20120058987-A1 | THERAPEUTIC USES OF QUINAZOLINEDIONE DERIVATIVES | SLC5A2, SLC5A1, PPARD | EPHX2 2433/4885GPR119 134/4885MEN1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.